10,500 Merck & Co., Inc. $MRK Shares Bought by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. raised its position in Merck & Co., Inc. (NYSE:MRK) by 1.5% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 730,921 shares of the company’s stock after buying an additional 10,500 shares during the period. Merck & Co., Inc. comprises approximately 0.8% of Mn Services Vermogensbeheer B.V.’s holdings, making the stock its 28th largest holding. Mn Services Vermogensbeheer B.V.’s holdings in Merck & Co., Inc. were worth $106,210,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $26,000. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $27,000. Horizons Wealth Management bought a new stake in shares of Merck & Co., Inc. during the third quarter worth approximately $30,000. Graney & King LLC raised its stake in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after buying an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC acquired a new position in Merck & Co., Inc. in the second quarter valued at approximately $41,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on MRK shares. The Goldman Sachs Group lifted their price objective on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, August 21st. UBS Group increased their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. HSBC raised their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Bank of America boosted their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, Royal Bank Of Canada downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and increased their price target for the company from $142.00 to $150.00 in a research report on Thursday, August 20th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $151.32.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 228,238 shares of company stock valued at $29,977,783 in the last 90 days. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with a PD-1/PD-L1 inhibitor. The decision expands Merck’s oncology portfolio and could create another commercial opportunity beyond Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, although that program remains at a very early stage. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating while trimming its price target modestly to $177, implying substantial upside based on the referenced price. The call indicates continued confidence in Merck’s long-term earnings and pipeline prospects. Morgan Stanley Raises Merck Analyst View
• Positive Sentiment: Merck’s shareholder dividend was highlighted as part of its income appeal, which may support investor interest while the company navigates product-cycle and patent risks. Merck Dividend Payment
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $145 but retained a “neutral” rating, suggesting limited near-term upside and a cautious view of Merck’s growth outlook. Cantor Fitzgerald Merck Price Target
• Neutral Sentiment: Articles comparing Innoviva and Merck frame MRK as a large-cap pharmaceutical value candidate, but provide no new company-specific catalyst likely to materially change the stock’s valuation today. INVA vs. MRK: Which Stock Is the Better Value Option?
• Negative Sentiment: A Dutch court granted Halozyme an injunction blocking Merck’s subcutaneous Keytruda in eight European markets. The ruling could delay or restrict commercialization of a potentially more convenient Keytruda formulation and heightens litigation risk. Halozyme Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Industry analysis identifies Merck as particularly exposed to near-term generic competition as major products approach patent losses. That raises concerns about revenue durability and increases the importance of successful launches such as WELIREG. Pharma’s $500 Billion Patent Problem

Merck & Co., Inc. Price Performance

NYSE MRK opened at $142.45 on Friday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a market cap of $351.45 billion, a price-to-earnings ratio of 113.96, a PEG ratio of 6.42 and a beta of 0.21. The business has a 50 day simple moving average of $143.59 and a 200 day simple moving average of $128.16. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the prior year, the company earned $2.13 earnings per share. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts anticipate that Merck & Co., Inc. will post 2.67 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.